A prospective non-randomized trial: the use of platinum-containing chemotherapy with mitomycin for relapses of BRCA1-associated ovarian cancer


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background. BRCA1-associated ovarian cancer (OC) demonstrates a high sensitivity to DNA-damaging agents, but the most effective drug regimen for disease recurrence has not been determined. Objective. Evaluation of the efficacy of platinum-containing chemotherapy with mitomycin for the recurrence of OC with BRCA1 gene mutation. Methods. The study included 12 patients with relapse of a BRCA-associated OC who were treated in the N.N. Petrov NMRCO of the Ministry of Health of the Russian Federation from 2015 to 2017. Mitomycin (10 mg/m2) and cisplatin (100 mg/m2) or carboplatin (AUC6) preparations were administered intravenously every 3-4 weeks. Results. Complete clinical regression was recorded in 5/12 (41.67%) patients, partial regression - in 5/12 (41.67%), stabilization of the disease - in 2/12 (16.67%). A decrease in Ca-125 level was observed in all patients during treatment. Median progression-free survival was 11.5 months. Grade 3-4 toxicity, according to NCI CTC criteria, was detected in 4/12 (33.33%) patients. Conclusion The results of the trial can serve as a basis for planning a randomized study on the efficacy and toxicity of combined platinum-containing chemotherapy with mitomycin for relapses of BRCA1-associated OC.

全文:

受限制的访问

作者简介

Kh. Kotiv

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

Email: Kotiv.onc@gmail.com
PhD, Researcher at the Research Department of Oncogynecology 68, Leningradskaya Street, Pesochny settlement, St. Petersburg 197758, Russian Federation

M. Yakovleva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. Sokolenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

T. Gorodnova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. Ivantsov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

E. Nekrasova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

O. Smirnova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. Sidoruk

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

St. Petersburg, Russia

N. Bondarev

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

I. Meshkova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

N. Mikaya

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

S. Petrik

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. Urmancheeva

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

St. Petersburg, Russia

E. Ulrikh

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

St. Petersburg, Russia

S. Protsenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. Belyaev

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

St. Petersburg, Russia

E. Imyanitov

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

St. Petersburg, Russia

I. Berlev

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

St. Petersburg, Russia

参考

  1. Горбунова А.В. Повторные циторедуктивные операции и вторая линия химиотерапии при лечении рецидивов рака яичников. Дисс. канд. мед. наук. М., 2001. C. 132-50
  2. Портнова Н.И. Выявляемость злокачественных опухолей яичников в условиях диспансеризации и причины смерти больных. Дис. канд. мед. наук. 2001. 147 с
  3. Armstrong D.K. Relapsed ovarian cancer: Challenges and management strategies for a chronoic disease. Oncologist. 2002;7(5):20-28.
  4. Alsop K, Fereday S., Meldrum C., et al. BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654-63. Doi: 10.1200/ JCO.2011.39.8545.
  5. Kaye S.B., Lubinski J., Matulonis U., et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib,a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372-79. doi: 10.1200/JCO.2011.36.9215.
  6. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. J Clin Oncol. 2014;32(13):1302-308. doi: 10.1200/JCO.2013.51.4489.
  7. Tan D.S.P, Kaye S.B. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? Am Soc Clin Oncol. Educ. B. 2015;35:114-21. doi: 10.14694/EdBook_ AM.2015.35.114.
  8. Stordal B., Davey R. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: Role of BRCA1. Curr Cancer Drug Targets. Bentham Science. 2009;9(3):354-65.
  9. Sung M, Giannakakou Ft BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling. Oncogene. 2014;33(11):1418-28. Doi: 10.1038/ onc.2013.85.
  10. Hollis R.L., Churchman M, Gourley C. Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. Onco Targets Ther Dove Press. 2017;10:2539-51. doi: 10.2147/OTT.S102569.
  11. Leunen K., Cadron I., Van Gorp T, et. al. Does Paclitaxel-Carboplatin Chemotherapy in a Dose-Dense Regimen Enhance Survival of BRCA-Related Ovarian Cancer Patients? Int J Gynecol Cancer. 2009;19:(9):1501-504. Doi: 10.1111/ IGC.0b013e3181bb703f.
  12. Tan D.S., Yap T.A., Hutka M., et al. Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. Eur J Cancer. 2013;49(6):1246-53. doi: 10.1016/j.ejca.2012.11.016.
  13. Samou§lian V, Maugard C.M., Jolicoeur M., et al. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGF?-RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemother Pharmacol. 2004;54(6): 497-504.
  14. Tagliaferri P, Ventura M., Baudi F., et al. BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality? J Ovarian Res BioMed Central. 2009;2:14. doi: 10.1186/1757-2215-2-14.
  15. Safra T., Rogowski O., Muggia F.M. The Effect of Germ-Line BRCA Mutations on Response to Chemotherapy and Outcome of Recurrent Ovarian Cancer. Int J Gynecol Cancer. 2014;24(3):488-95. doi: 10.1097/IGC.0000000000000086.
  16. Hyman D.M., Zhou Q., Arnold A.G., et al. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol. NIH Public Access. 2011;123(2):196-99. doi: 10.1016/j.ygyno.2011.07.019.
  17. Thorn C.F, Oshiro C., Marsh S., et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. NIH Public Access. 2011;21(7):440-46. Doi: 10.1097/ FPC.0b013e32833ffb56.
  18. Mantia-Smaldone G., Ronner L., Blair A., et al. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1- deficient ovarian tumors and can be exploited to improve treatment response in a mouse model. Gynecol Oncol. 2014;133(3):584-90. Doi: 10.1016/j. ygyno.2014.03.565.
  19. Moiseyenko V.M., Chubenko V.A., Moiseyenko F.V., et al. Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation. Med Oncol. Springer US. 2014;31(10):199. doi: 10.1007/s12032-014-0199-x.
  20. Gorodnova T.V, Kotiv K.B., Ivantsov A.O., et al. Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer. Int J Gynecol Cancer. 2018;28(8):1498-1506. doi: 10.1097/IGC.0000000000001352.
  21. Городнова Т.В., Соколенко А.П., Иванцов А.О., и др. Системная терапия распространенного рака яичников у носительниц мутаций в гене BRCA1 - новые лечебные подходы: результаты проспективного нерандомизированного многоцентрового исследования. Фарматека. 2018;7:57-64.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##